Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Bristol Myers’ (BMY) is striving hard for the label expansion of its key drugs. The company’s growth portfolio comprises ...

Despite not meeting the endpoint, subjects have experienced a meaningful improvement in RBC transfusion independence.

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

Despite the failure, BMS remains “encouraged” by Reblozyl’s clinical activity in myelofibrosis-associated anemia and will approach regulators to discuss potential submissions for this indication, for ...

Bristol Myers' Reblozyl missed its primary goal in a Phase 3 anemia trial but showed positive secondary outcomes in ...

Bristol Myers on Friday said the Phase 3 study of Reblozyl with concomitant janus-kinase-inhibitor therapy didn't meet its primary endpoint of red-blood-cell transfusion independence in adults with ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. The company has ...

Reblozyl® (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes ...

US pharma major Bristol Myers Squibb’s shares remained steady, despite the company reporting disappointing results from its ...